Recent advances in metabolomics analysis for early drug development.
Drug discovery
Flux
LC-MS
Lipidomics
Metabolomic
NMR
Target
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
24
12
2021
revised:
25
01
2022
accepted:
21
02
2022
pubmed:
27
2
2022
medline:
25
5
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
The pharmaceutical industry adapted proteomics and other 'omics technologies for drug research early following their initial introduction. Although metabolomics lacked behind in this development, it has now become an accepted and widely applied approach in early drug development. Over the past few decades, metabolomics has evolved from a pure exploratory tool to a more mature and quantitative biochemical technology. Several metabolomics-based platforms are now applied during the early phases of drug discovery. Metabolomics analysis assists in the definition of the physiological response and target engagement (TE) markers as well as elucidation of the mode of action (MoA) of drug candidates under investigation. In this review, we highlight recent examples and novel developments of metabolomics analyses applied during early drug development.
Identifiants
pubmed: 35218927
pii: S1359-6446(22)00076-9
doi: 10.1016/j.drudis.2022.02.018
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1763-1773Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.